Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Rheumatology

What Baseline Tests Are Recommended After RP Diagnosis?

At a Glance

After a relapsing polychondritis diagnosis, there is no single required test panel. A rheumatologist tailors blood work and, when appropriate, breathing, heart, aorta, eye, and hearing evaluations to symptoms, examination, age, and medical history.

When you are diagnosed with relapsing polychondritis (RP), your rheumatologist or multidisciplinary care team will likely recommend a baseline medical evaluation. Because RP can affect cartilage and connective tissue throughout the body—including the airways, heart, and blood vessels—disease activity can sometimes occur in these critical areas before you notice symptoms [1][2].

However, there is no single blood test that confirms RP, and there is no universally mandated “one-size-fits-all” panel of tests. Your baseline testing plan will be individualized based on your specific symptoms, physical examination, age, and medical history. A comprehensive evaluation helps identify any hidden inflammation early and provides a snapshot of your organ function to compare against in the future [3].

When to Seek Urgent Care
While baseline testing is important for understanding your overall health, it is meant for stable evaluation. Do not wait for a scheduled scan or baseline test if you experience any of the following:

  • New or rapidly worsening shortness of breath
  • Noisy breathing (stridor) or an inability to lie flat
  • Sudden chest, back, or abdominal pain
  • Sudden vision loss, severe eye pain, or sudden hearing loss
    Seek emergency medical care immediately for these symptoms.

Airway and Lung Assessment

Because airway involvement is a known complication of RP, your team may consider assessing your respiratory tract even if you feel you are breathing normally. In one study of 173 RP patients, 66% of those without breathing symptoms showed some radiographic airway abnormalities on imaging [4]. Common baseline assessments include:

  • Pulmonary Function Tests (PFTs): These breathing tests measure lung capacity and airflow. They often include a flow-volume loop, which helps identify if the central airways are narrowed [5][6].
  • Dynamic Chest CT Scan: If considered appropriate by your doctor, this specialized CT scan covers the chest and neck (cervical trachea). Images are taken during inhalation and forced exhalation to see if the airways collapse during breathing [1][5]. Your doctor will weigh the diagnostic benefits of this test against the exposure to radiation and contrast dye.

Bronchoscopy (a procedure where a flexible camera is inserted into the airways) is generally avoided for routine screening in RP because it can irritate fragile cartilage and provoke airway spasms; it is usually reserved for specific situations where specialists need direct airway inspection or to perform an intervention [1][7].

Cardiovascular Screening

RP can affect the heart valves, heart muscle, and the aorta (the body’s main artery) [8]. Because early cardiovascular changes often do not cause symptoms, your doctor may consider:

  • Electrocardiogram (ECG) and Echocardiogram: An ECG checks the heart’s electrical rhythm, while an echocardiogram (an ultrasound of the heart) evaluates the heart muscle and ensures the valves are functioning properly [9].
  • Aortic Imaging: A specialized CT angiography (CTA) or magnetic resonance angiography (MRA) may be ordered to check the aorta for inflammation or widening (aneurysm) [10][11]. In a review of 114 RP patients with known aortic involvement, 19% had no symptoms when the aortic issue was discovered [2]. Your rheumatologist or cardiologist will decide if this imaging is necessary for you based on your personal risk factors.

Blood Tests and VEXAS Syndrome

Routine baseline blood work often includes a complete blood count (CBC), kidney and liver function panels, and inflammatory markers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). It is important to know that having normal CRP or ESR levels does not guarantee the absence of RP activity; these labs are just one piece of the clinical puzzle [12][13].

The VEXAS Evaluation
Your doctor will review your CBC for clues of VEXAS syndrome, a condition that can closely mimic RP. Unlike inherited genetic diseases, VEXAS is caused by an acquired mutation in the UBA1 gene within blood-forming cells, meaning it is not passed down to your children [14]. Testing for VEXAS is typically considered for patients—most commonly men whose symptoms began after age 45, though it rarely occurs in women—who have treatment-resistant inflammation combined with specific blood abnormalities like macrocytosis (unusually large red blood cells) or low platelets [15][16].

Vision and Hearing Examinations

Because RP frequently causes inflammation in the cartilage of the ears and the connective tissue of the eyes, baseline evaluations by an ophthalmologist (eye specialist) or audiologist (hearing specialist) are often considered [17]. These exams are especially important if you have symptoms like eye redness, pain, light sensitivity, ringing in the ears, or balance issues [18][19], but they can also establish a helpful baseline for future comparison if new symptoms arise.

Common questions in this guide

What baseline tests are commonly considered after an RP diagnosis?
There is no single required test panel after a relapsing polychondritis diagnosis. Depending on your symptoms and medical history, clinicians may consider blood tests, breathing tests, heart evaluation, aortic imaging, and eye or hearing examinations. The goal is to look for organ involvement and create results for future comparison.
Should I have airway testing even if I do not feel short of breath?
Your care team may consider pulmonary function tests, including a flow-volume loop, even without breathing symptoms because airway changes can be silent. A dynamic CT of the chest and neck may be considered to look for airway narrowing or collapse. Routine bronchoscopy is generally avoided for screening because it can irritate fragile airway cartilage.
What heart and aorta tests might be needed with relapsing polychondritis?
An ECG checks the heart's electrical rhythm, and an echocardiogram uses ultrasound to assess the heart muscle and valves. Depending on your symptoms and risk factors, CT angiography or magnetic resonance angiography may be used to examine the aorta for inflammation or widening. Your rheumatologist or cardiologist should individualize this decision.
What blood tests are used to assess RP and possible VEXAS syndrome?
Baseline blood work may include a complete blood count, kidney and liver tests, C-reactive protein, and erythrocyte sedimentation rate. Normal inflammatory markers do not prove that RP is inactive. If inflammation is difficult to control and the blood count shows unusually large red cells or low platelets, especially in a man whose symptoms began after age 45, your doctor may consider testing for VEXAS, an acquired condition related to changes in the UBA1 gene.
Why might I need eye and hearing examinations after an RP diagnosis?
An eye examination and hearing evaluation can document a baseline for comparison if symptoms develop later. They are especially important if you have eye redness, pain or light sensitivity, ringing in the ears, hearing changes, or balance problems. Your care team can determine which specialists and tests fit your situation.
Which symptoms require emergency care instead of waiting for baseline testing?
Seek emergency care for new or rapidly worsening shortness of breath, noisy breathing, or an inability to lie flat. Sudden chest, back, or abdominal pain, sudden vision loss or severe eye pain, and sudden hearing loss also require immediate evaluation. Do not wait for a planned baseline test when these symptoms occur.

Get notified when new evidence is published on Relapsing polychondritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Tracheobronchial involvement of relapsing polychondritis.

    de Montmollin N, Dusser D, Lorut C, et al.

    Autoimmunity reviews 2019; (18(9)):102353 doi:10.1016/j.autrev.2019.102353.

    PMID: 31323366
  2. 2

    Aortic involvement in relapsing polychondritis: case-based review.

    Erdogan M, Esatoglu SN, Hatemi G, Hamuryudan V

    Rheumatology international 2021; (41(4)):827-837 doi:10.1007/s00296-019-04468-5.

    PMID: 31768631
  3. 3

    Elucidation of predictors of disease progression in patients with relapsing polychondritis at the onset: potential impact on patient monitoring.

    Shimizu J, Yamano Y, Kawahata K, Suzuki N

    BMC rheumatology 2020; (4()):41 doi:10.1186/s41927-020-00141-8.

    PMID: 32944685
  4. 4

    Laryngeal involvement in relapsing polychondritis: clinical and CT findings in 173 patients.

    Bai X, Yu R, Wang Z

    RMD open 2025; (11(2)) doi:10.1136/rmdopen-2024-005397.

    PMID: 40345708
  5. 5

    Correlation between Computed Tomographic Analysis and Pulmonary Function Measurements in Patients with Relapsing Polychondritis.

    Tsuruoka H, Handa H, Yamashiro T, et al.

    Respiration; international review of thoracic diseases 2021; (100(2)):109-115 doi:10.1159/000511437.

    PMID: 33477148
  6. 6

    Quantitative Computed Tomography Measurement of Tracheal Cross-Sectional Areas in Relapsing Polychondritis: Correlations with Spirometric Values.

    Usuba A, Yamashiro T, Handa H, et al.

    Respiration; international review of thoracic diseases 2015; (90(6)):468-473 doi:10.1159/000441303.

    PMID: 26509473
  7. 7

    Risk factors associated with severe adverse events in patients with relapsing polychondritis undergoing flexible bronchoscopy.

    Wang ST, Wang J, Gao X, et al.

    Orphanet journal of rare diseases 2024; (19(1)):54 doi:10.1186/s13023-024-03061-9.

    PMID: 38336719
  8. 8

    Clinical characteristics and associated factors of cardiovascular involvement in patients with relapsing polychondritis.

    Shi T, Liu QM, Wen XH, et al.

    Frontiers in medicine 2026; (13()):1877659 doi:10.3389/fmed.2026.1877659.

    PMID: 42601895
  9. 9

    Relapsing polychondritis: focus on cardiac involvement.

    Yin R, Zhao M, Xu D, et al.

    Frontiers in immunology 2023; (14()):1218475 doi:10.3389/fimmu.2023.1218475.

    PMID: 37771578
  10. 10

    Large-vessel Vasculitis Affecting the Aorta and its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature.

    Tomelleri A, Campochiaro C, Sartorelli S, et al.

    The Journal of rheumatology 2020; (47(12)):1780-1784 doi:10.3899/jrheum.190862.

    PMID: 31839593
  11. 11

    Aortic involvement in relapsing polychondritis.

    Le Besnerais M, Arnaud L, Boutémy J, et al.

    Joint bone spine 2018; (85(3)):345-351 doi:10.1016/j.jbspin.2017.05.009.

    PMID: 28528280
  12. 12

    Imaging diagnosis in relapsing polychondritis and correlation with clinical and serological data.

    Thaiss WM, Nikolaou K, Spengler W, et al.

    Skeletal radiology 2016; (45(3)):339-46 doi:10.1007/s00256-015-2270-x.

    PMID: 26490679
  13. 13

    What are risk factors for relapse in relapsing polychondritis? A retrospective study.

    Zhang N, Liu S, Liu Y, et al.

    Clinical rheumatology 2026; (45(2)):1155-1164 doi:10.1007/s10067-025-07831-z.

    PMID: 41413312
  14. 14

    Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome.

    Maeda A, Tsuchida N, Uchiyama Y, et al.

    Rheumatology (Oxford, England) 2024; (63(8)):2056-2064 doi:10.1093/rheumatology/kead425.

    PMID: 37606963
  15. 15

    Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS.

    Ferrada MA, Sikora KA, Luo Y, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(10)):1886-1895 doi:10.1002/art.41743.

    PMID: 33779074
  16. 16

    Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients.

    Khitri MY, Guedon AF, Georgin-Lavialle S, et al.

    RMD open 2022; (8(2)) doi:10.1136/rmdopen-2022-002255.

    PMID: 35868738
  17. 17

    Relapsing polychondritis: A clinical update.

    Longo L, Greco A, Rea A, et al.

    Autoimmunity reviews 2016; (15(6)):539-43.

    PMID: 26876384
  18. 18

    Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients.

    Georgin-Lavialle S, Terrier B, Guedon AF, et al.

    The British journal of dermatology 2022; (186(3)):564-574 doi:10.1111/bjd.20805.

    PMID: 34632574
  19. 19

    Patient Perception of Disease-Related Symptoms and Complications in Relapsing Polychondritis.

    Ferrada MA, Grayson PC, Banerjee S, et al.

    Arthritis care & research 2018; (70(8)):1124-1131 doi:10.1002/acr.23492.

    PMID: 29245173

This page describes possible baseline evaluations after a relapsing polychondritis diagnosis for education only and does not replace medical advice. Your rheumatologist and relevant specialists should decide which tests are appropriate and how to interpret your results.